Evaluation of the antiemetic effect of domperidon in patients treated with cytostatic drugs.
Forty patients with various neoplastic syndromes received domperidon as a drug reducing nausea and vomiting. The drug prevents in the daily dose of 30 mg completely the occurrence of nausea and vomiting in 30% of the patients and in 58% considerably reduces their intensity. The dose of 60 mg abolishes nausea and vomiting in 60% of the patients and alleviates in 35%. The drug had been administered through the whole period of chemotherapy without any side effects which may be attributed to its antagonist action to dopamine.
Department of Internal Diseases and Haematology, University Medical School in Warsaw.
A
A
Polubiec
Z
Z
Krasnopolska-Polanczky
W
W
Duda-Król
I
I
Jórasz
J
J
Witkowski
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D004294:Domperidone / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology; D012720:Severity of Illness Index; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology
D004294:Domperidone